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magnetic, electrical, and optical properties for concomitant imaging. This has been accomplished by
incorporating various imaging agents, such as fluorescent dyes, biomarkers, quantum dots, metal composites,
and magnetic nanoparticles. We discussed theranostic nanomaterial synthesis, carrier fabrication and its
applications. By presenting this comprehensive review of the state-of-the-art, we demonstrated that polymeric
multifunctional nanomaterials exhibit distinctive advantages and features in theranostics.
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Abstract: The nanocarriers provide a platform to integrate therapy and diagnostics, which is an 
emerging direction in medical practice. Beyond simply therapeutic functionality, theranostic 
nanomaterials have been designed to deliver multiple components and imaging agents, facilitating 
simultaneous and synergistic diagnosis and therapies. In this article, polymeric materials with diverse 
functionalities and properties for manufacturing theranostic nanomaterials are discussed and compared. 
We focused on recent advancements of polymeric multifunctional nanomaterials for synergistic 
theranostics. The drugs and imaging agents were encapsulated within and/or conjugated to the surface of 
the nanocarriers, according to the fabricating process and carrier type. In parallel with therapy, polymeric 
multifunctional nanomaterials can be exploited to exhibit distinctively magnetic, electrical, and optical 
properties for concomitant imaging. This has been accomplished by incorporating various imaging agents, 
such as fluorescent dyes, biomarkers, quantum dots, metal composites, and magnetic nanoparticles. We 
discussed theranostic nanomaterial synthesis, carrier fabrication and its applications. By presenting this 
comprehensive review of the state-of-the-art, we demonstrated that polymeric multifunctional 
nanomaterials exhibit distinctive advantages and features in theranostics. 
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1. Introduction 
Nanocarriers provide a platform for theranostics to concurrently realize therapy and diagnosis 1. 
Polymeric drug delivery systems have been widely studied for years. In the 1960s, polymers were mainly 
utilized for wound healing, blood plasma expanding, and injectable drug releasing 2, 3. Normally, 
polymeric nanoparticles are used to deliver drugs to affected tissues and to regulate the release kinetics of 
the drugs in the body. Prior to treatment, clinical diagnosis is an essential step. Recently, researchers are 
aiming to achieve diagnosis and therapy in one combined step. Clinicians may monitor drug localization 
and image the result of the treatment simultaneously after drug administration. 
Advances in nanotechnology significantly influenced the treatment and detection of diseases 4-7. The 
strategies used in advanced theranostics, such as polymer conjugations, solid lipid nanoparticles, 
dendrimers, micelles, magnetic nanoparticles, silica nanoparticles, and quantum dots, may achieve fewer 
side effects and better synergistic outcomes 8, 9. The goal of theranostics is to diagnose and treat a disease 
at its earliest stage. Advanced theranostic nanomedicine possessing multifunctional properties in nature 
has the ability to diagnose and deliver therapy to the diseased cells with the help of biomarkers and 
targeting ligands 10-13. Conjugation, entrapment, absorption, and encapsulation of drugs and diagnostic 
agents in polymeric particles can result in combined loading, ultimately achieving the function of 
theranostics at the molecular and cellular levels 14-16.  
The therapeutic agents used in theranostic nanomedicine include small chemicals, genetic materials, 
proteins, and peptides. Imaging techniques that are used in theranostics are mainly dependent on the 
contrast agent used 17. As a 2D imaging instrument, gamma scintigraphy is more efficient in visualizing 
drug localization through pulmonary and oral routes. As a 3D imaging system, positron emission 
tomography (PET) and single photon emission computed tomography (SPECT) can be used to observe 
regional depositions of drugs in the lung. However, some practical hurdles limit the clinical application of 
SPECT and PET 18. In order to deliver active drugs and imaging agents simultaneously, drug delivery 
systems (DDS) have been designed to control therapeutic agents’ release to treat illnesses and to mark the 
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affected tissues or cells. For specific conditions like hypoxia, the control of pH, temperature, light, and 
ultrasound has been carried out to precisely regulate the pharmacokinetics of the drugs and imaging 
agents 19, 20. Contrast agents in DDS can also be used to monitor the accumulation of particles in tissues 
and to observe the interactions between the carriers and the microenvironment through a non-invasive 
way. In this review, we summarize the recent developments in multifunctional polymeric nanomaterial 
theranostic platforms, for instance drug-polymer conjugates, solid lipid nanoparticles, dendrimers, 
micelles, magnetic nanoparticles, silica nanoparticles, polymeric/magnetic nanoparticles, polymeric/silica 
nanoparticles, and quantum dots 21, 22. We hope that this review can provide a broad overview of the scope 
of multifunctional polymeric nanomaterials in theranostics. 
2. Drug-polymer conjugates 
Polymers with long chain molecules are linked by covalent bonds and can be used to regulate the 
pharmacokinetics of drugs and/or imaging agents in the body. Drug-polymer conjugates are formed 
through the connection of various functional groups between the polymer and the drug or imaging agents, 
providing real-time observations on the localization and delivery efficiency of the conjugates. For 
example, tumor angiogenesis promotes the growth of malignant cells. The arginine-glycine-aspartic 
(RGD) sequence can interact with αvβ3 integrins and direct the targeted delivery of nanocarriers to tumor 
vessels, enhancing their accumulation in tumor tissues. Yuan et al. synthesized poly [N-(2-hydroxypropyl) 
methacrylamide (HPMA)-c (RGDyK)-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid] 
(DOTA)-64Cu copolymers and evaluated the in vivo tumor localization of theranostic scaffolds by PET. 
The RGD sequence enhanced the radioactivity of the copolymer in prostate cancer xenografts from 1.29% 
± 0.26% injected dose (ID)/g to 2.75% ± 0.34% ID/g (2.13 fold). The data showed that the copolymer 
could potentially be used to prepare new nanocarriers for tumor imaging and radiochemotherapy 23.  
Similarly, Zarabi et al. replaced Cu with Gd and found that the polymeric conjugates possessed 
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stronger relaxivities than that of Gd-DOTA. Conjugation did not impact the affinity of RGD for αvβ3 
integrins on endothelial cells and MDA-MB-231 breast cancer cells 24. The RGD sequence plays another 
vital role in the targeted delivery of nanocarriers. Mitra et al. compared the localization of HPMA- 
technetium-99m-RGD4C (sequence: KACDCRGDCFCG) and HPMA-technetium-99m 
(99mTc(CO)3)-RGD4E (KACDCRGECFCG) at the sites of neovascular angiogenesis and found that the 
scintigraphic images showed higher biodistribution of the former conjugates, based on the radioactivity 25. 
However, the chelator of 99mTc(CO)3 (N-L-bis(2-pyridylmethyl)-L-lysine (RGD4C-DPK)) decreased the 
accumulation of conjugates to some extent 26. Poly(L-glutamic acid) is another candidate for diagnosis 
and therapeutics. Ye et al. connected poly(L-glutamic acid) with 1,6-hexanediamine-(Gd-DO3A) and 
observed the influence of molecular weight on the conjugates’ pharmacokinetics. The data from contrast 
enhanced Magnetic Resonance Imaging (MRI) showed that the copolymer with the smallest molecular 
weight (28 kD) was most rapidly removed from the body, with the lowest tumor accumulation. On the 
contrary, other larger molecules (87 and 50 kD) improved blood circulation times and exhibited stronger 
signals in the tumor tissues 27 (Fig. 1).  
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Fig. 1 Representative coronal images of mice organs and xenografts by MR after intravenous administration of 
PGA-1,6-hexanediamine-(Gd-DO3A). Time points for images are: (a) before tests, (b) 1 min, (c) 11 min, (d) 20 min, 
(e) 30 min, (f) 60 min, (g) 120 min, (h) 180 min, (i) 240 min and (j) 24 h. Arrows: (1) liver, (2) heart, (3) tumor 
tissue, and signal intensity of (4) cross-section in tumor tissue (reprinted with permission from ref. 27).  
3. Nanoparticles 
Nanoparticles are a category of nanoscale carriers based on polymers for drug delivery and diagnosis. 
These nanoscale particulates may consist of multiple functional units. They have been extensively 
employed to control the delivery of encapsulated drugs and imaging agents for both diagnosis and 
therapy. 
3.1. Solid lipid nanoparticles 
Solid lipid nanoparticles (SLNs) are DDS with improved stability compared with nanoparticles, 
liposomes, and emulsions. SLNs possess other advantages such as controlled release, targeted delivery, 
and high loading efficiency while avoiding the use of organic solvents 28, 29. The dissolved or dispersed 
drug exists in the solid hydrophobic core, while excipients, including surfactants and phospholipids, are 
generally recognized as safe for clinical therapy. However, the drawbacks of SLNs, such as size growth, 
burst release at the earlier stages, tendency of uncontrollable gelation, and dynamics of polymeric 
transitions, limit their application 30. Several methods for SLN preparation have been published, including 
high speed/pressure homogenization31, 32, double emulsion33, ultrasound dispersion34, and use of 
membrane contactors35, 36. Similar to other nanomaterials, SLNs can be used as theranostic formulations 
to deliver therapeutic and diagnostic agents to targeted sites. 
Drugs cannot effectively accumulate in tumor tissues through conventional administration routes. 
Lymphatic delivery of SLNs can enhance the bioavailability of drugs after oral administration 37. Reddy 
et al. prepared solid lipid tripalmitin nanoparticles labeled with 99mTc and containing etoposide. They 
evaluated the biodistribution and tumor uptake of nanocarriers in mice through subcutaneous, intravenous, 
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and intraperitoneal injection. The data showed that subcutaneous injection decreased the biodistribution 
of nanoparticles in all organs. Moreover, intraperitoneal administration increased the accumulation of 
particles in tissues compared with that observed after delivery of free drug via the same route and 
intravenous administration. However, nanoparticles accumulated in the tumor in a slower and more 
progressive way after subcutaneous administration, and the accumulation was significantly higher than 
that induced by intravenous (59 fold) or intraperitoneal injection (8 fold) 24 h after administration 38. 
Similarly, Cavalli et al. confirmed that SLNs containing taurocholate, stearic acid, and 
phosphatidylcholine increased the absorption of tobramycin after duodenal administration and extended 
the half time of the drug in blood from 57 min (free drug) to 1371 min (drug in SLNs) 39.  
Bae et al. entrapped low-density lipoprotein (LDL), paclitaxel, and quantum dots (QDs) into SLNs 
(PQSLNs) and decorated their surface with siRNA. The particles efficiently delivered anti-cancer drugs 
and oligonucleotides into lung cancer cells. The data confirmed that siRNA could promote the anti-cancer 
activities of paclitaxel in a synergistic way. The fluorescent signal obtained from the quantum dots in the 
SLNs enabled the visualization of the intracellular trafficking of particles in the cells. The results 
suggested that SLNs can be used as a multifunctional platform to efficiently treat cancers (Fig. 2) 40. 
 
Fig. 2 Schematic of PQSLNs, as a theranostic formulation, entrapping quantum dot and paclitaxel and coated with 
siRNA on the surface of nanoparticles to treat cancer in a synergistic way (reprinted with permission from ref. 40). 
3.2. Dendrimers 
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The elementary structure of dendrimers presents a tree-like branched architecture, providing room 
for a small molecule to be incorporated 41. Dendrimers, as nanocarriers, have tunable nanoparticle sizes 
from 10 to 100 nm. They are able to solubilize hydrophobic drugs because of their unique structure. The 
higher generation dendrimers with a number of branches and cavities are able hold dyes, small molecules, 
diagnostic agents, and other therapeutics for theranostic applications. Dendrimers were used to load 
cisplatin for cancer treatment and was proven to have a stronger effect on the malignant cells 42. The 
monodispersed macromolecules on the surface of the dendrimers possess a few reactive end groups to 
modify the properties of the carriers. Weck’s group designed a multifunctional dendrimer based on 
polyamine. The active end groups of the dendrimers included nine amines, nine azides, and 54 acids, 
connecting with a near-infrared (NIR) cyanine dye. This new material exhibited no toxicity to human 
glioblastoma cells (T98G) and might be a promising material for theranostics (Fig. 3) 43.  
 
 
Fig. 3 Advanced dendrimer with functional termini, including NIR fluoresceins, acidic acid, and azide groups for 
connection with therapeutics or imaging reagents (reprinted with permission from ref. 43). 
 
Phthalocyanines are excellent dyes that can be excited to produce near-infrared (NIR) light. This dye 
is believed to be a theranostic agent to monitor the biodistribution of nanoparticles for the treatment of 
deep tumors. However, the dye has hydrophobic properties, high aggregation, and low specificity to 
cancer cells, and therefore, it cannot be used to efficiently treat cancer in clinic applications. Taratula et al. 
synthesized novel polypropylenimine dendrimer carriers to deliver phthalocyanines into tumors. The dye 
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was modified with a hydrophobic molecule to increase the encapsulation efficiency in the dendrimer 
while luteinizing hormone-releasing hormone (LHRH) and poly (ethylene glycol) (PEG) surface coating 
of the carriers enhanced the biocompatibility and targeted delivery of the dye. The in vivo imaging studies 
confirmed that the dendrimer improved the localization of the dye in the tumor tissues after intravenous 
injection 44. 
Radiovirotherapy is a method to use viruses to deliver radioisotopics into the body; it is another 
strategy to eradicate tumors. Grünwald et al. coated adenovirus that was inserted with the gene of the 
theranostic sodium-iodide symporter using cationic poly (amidoamine) (PAMAM) dendrimers. In 
addition, the dendrimer was decorated with specific ligand GE11 of epidermal growth factor receptor 
(EGFR) to direct the delivery of transfected adenovirus to tumor sites. At fourth day of intravenous 
adenovirus injection, mice were injected intraperitoneally with 18.5 MBq 123I, and radioiodine 
accumulation was scanned with gamma camera imaging equipment. The high expression of 
sodium-iodide symporter in the tumor by targeted delivery of the dendrimers enhanced the accumulation 
of 123I and promoted the killing effects of radioiodine on the malignant cells. The competitive affinity of 
EGFR-specific antibodies significantly reduced the biodistribution of 123I in the tumor tissues, which 
supported that EGFR, and not coxsackie-adenovirus receptors, conferred the targeting function of the 
carriers. The existence of adenovirus in the liver was reduced by its shielding and targeting with EGFR 
specific ligand GE11-coated dendrimers, which protected the healthy liver from high exposure of 
radioiodine and increased the transduction efficiency in tumor tissues (Fig. 4) 45.  
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Fig. 4 The in vivo images of EGFR-specific accumulation by 124I-PET tracking. (a) The uncoated vector had high 
hepatic accumulation after administration showed in the middle with larger area (i.v.). (b) Adenovirius coated with 
PAMAM-G2-PEG-GE11 showed in the middle with larger area or (c) monoclonal anti-EGFR antibodies decreased 
radioiodine accumulation in the liver showed in the middle with larger area (reprinted with permission from ref. 45). 
 
3.3. Liposomes 
Liposomes are small bilayer vesicles with aqueous compartments enclosed by cholesterol and 
amphiphilic phospholipids. They constitute a nanotechnology-based drug delivery platform and are 
effective because of their size, characteristics, biodegradability, biocompatibility, immunogenicity, and 
low toxicity 46-48. Liposomes have great potential applications in drug delivery, molecular imaging, 
vaccine delivery, and gene therapy 16, 49-51 (Fig. 5). The disadvantages of liposomal vesicles are poor 
stability, low drug-loading efficiency, short circulation time in the blood, and fast drug release 52. 
Liposomes could be easily removed by macrophages in the immune system. To overcome the drawbacks 
of these vesicles, modifying the surfaces of the liposomes with PEG turns them into stealth liposomes, 
inhibiting the removal of the vesicles by macrophages and increasing the stability of the carriers. Because 
of the inhibition of stealth liposomes by lymphatic drainage and the inherently leaky vasculature within 
tumor tissues, liposomes can passively accumulate in solid tumors and deliver drugs to destroy malignant 
cells. PEG chains can also be conjugated with molecular biomarkers to develop advanced theranostic 
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liposomes.  
 
  
Fig. 5 (A) The ex vivo images of ischemic cardiac muscle and normal skeletal muscle 6 h after injection of cTnI 
antibody-modified liposomal 1, 1′-dioctadecyl-3, 3, 3′, 3′-tetramethylindotricarbocyanine iodide (DiR). (B) 
Fluorescence distribution of left ventricular sections from different animals administrated with PBS, unmodified 
liposomes, cTnI antibody-modified liposomes (cT-LIP), sham with cT-LIP, and free DiR groups. (C) Images of 
cardiac sections from animals injected with cT-LIP formulation (reprinted with permission from ref. 49). 
 
Researchers have designed anti-HSP72 gene-transfected stealth immunoliposomes loaded with 
imaging probes to track themselves by using various types of imaging equipment. The vesicles were 
further loaded with citicoline to simultaneously improve the symptoms of cerebral ischemia. The data 
confirmed that the immunoliposomes (80%) were able to accumulate in the peri-infarct region after MRI 
observation. The lesion volume of rats after the injection of immunoliposomes was up to 30% smaller 
than that of free citicoline 53. Wen et al. incorporated apomorphine and quantum dots (QDs) into 
theranostic liposomes, resulting in decreased accumulation in the liver and increased the distribution in 
the brain 54. QDs in the bilayer membrane of the liposomes were used to image the distribution of vesicles 
in the brain, while the drug in the inner core of the vesicles was used to treat brain disorders. The data 
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confirmed that after liposomal administration, the signal of theranostic liposomes in the animal brain was 
higher than that of free QDs. The ex vivo imaging of the organs also supported the above-discussed in 
vivo results. However, the signals in the liver and heart were decreased after liposomal administration. 
Apomorphine in the brain was enhanced by 2.4-fold after this incorporation. 
3.4. Polymeric micelles 
Polymeric micelles are self-assembling colloidal structures with a hydrophilic shell and a 
hydrophobic core. They have properties such as appropriate size range (20–200 nm) for penetrating the 
blood vessels, high solubility and stability, and long circulation in the body 55. The strong associations 
between the polymers and the drug, as well as the conjugation of the polymeric core or of the shell 
improve the stability of the carriers. The localization of the loaded drug within the particles depends on 
the properties of the drug, such as polarizability and hydrophobicity. In addition, targeted micelles can 
prevent premature drug release in the body.  
Kim et al. loaded doxorubicin (DOX) into folate-modified micelles and evaluated the therapeutic 
efficacy of the particles by in vivo studies. The growth of xenografts in nude mice, after administration of 
drug loaded pH sensitive micelles and non-sensitive micelles, was significantly delayed. However, free 
DOX was unable to inhibit the growth of tumor volume (an exponential growth curve). Monitoring of 
both micelles and free drug was carried out by intravital fluorescence microscopy from 0 to 60 min (0, 7, 
10, 20, and 60 min). The fluorescence signal of free DOX could be observed from 7 to 60 min. At 60 min, 
the signal after the administration of the drug-loaded pH-sensitive micelles was still maintained, while 
that of the blank pH-sensitive micelles began to decrease. In another study, a micelle system used to load 
cyanine dye and doxorubicin as a novel theranostic platform possessed multiple functionalities such as 
thermotherapy, near-infrared fluorescence (NIRF) imaging, and synergistic chemotherapy of cytotoxicity 
from DOX and singlet oxygen from the dye to tumor cells. The results suggested that the micelles were 
used as a theranostic platform for multi-synergistic therapy and cancer imaging 56 (Fig. 6). 
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Fig. 6. Synergistic mechanism of cyanine-loaded micelles for cancer therapy (reprinted with permission from ref. 
56). 
4. Nanocomposites 
Nanocomposites possess multifunctional properties and have many advantages for delivery of drugs 
and imaging agents. Nanocomposites can be modified with several ligands to achieve the goal of 
diagnosis, therapy, and entry of carriers across the tissue barrier 57. The ligands on the surface of 
nanocomposites enhance the binding affinity of the particles to the targeted cells. In the following part, 
multifunctional nanocomposites that carrying various targeting moieties for cancer therapy and diagnosis 
will be discussed. 
4.1. Polymeric/magnetic nanoparticles 
Polymeric/magnetic nanoparticles have been studied as theranostic platforms for various therapies 58. 
Magnetic nanoparticles are composed mainly of iron oxides made from magnetite or hematite 59. 
Magnetic iron oxide nanoparticles have found their way into different fields of medicine and can be 
synthesized by simple methods, including thermal decomposition and co-precipitation.  
 
Page 14 of 36Journal of Materials Chemistry B
Jo
ur
na
lo
fM
at
er
ia
ls
C
he
m
is
tr
y
B
A
cc
ep
te
d
M
an
us
cr
ip
t
15 
 
 
Fig. 7 Schematic process of scAbPSCA-docetaxel/SPIONs for prostate cancer (reprinted with permission from ref. 
67). 
 
Because of their magnetic properties and biocompatibility, superparamagnetic iron oxide 
nanoparticles (SPIONs) have been widely investigated. In MRI, SPIONs have been studied as T2 contrast 
agents. In addition, they have been used to deliver photodynamic therapeutic agents and chemical drugs 
as theranostics 60. The PEGylated SPIONs can improve colloidal stability and biocompatibility 61. Chen et 
al. synthesized SPIONs and conjugated folic acid through PEG linker on their surface 62. The SPIONs had 
good dispersibility and stability in various pH solutions. In addition, the clearance of SPIONs by 
macrophage was lower than superparamagnetic iron oxide associated with dextran (Feridex I.V.). SPIONs 
can also be coated with cell- or protein-resistant polymers such as poly(TMSMA-r-PEGMA) as MRI 
agents for in vivo cancer imaging 63. The modification of the antifouling polymer on the surface of SPION 
decreased the clearance of reticular endothelial system (RES) and elongated the circulating time of 
particles in the vessels. The synthesis of carbohydrate-coated SPIONs as MRI nanoprobes has also been 
designed to include the derivatives of D-mannose and D-glucosamine 64. Antibody-SPION conjugates can 
be synthesized via the ionic interactions between the nanoparticles and the antibody by using 
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immobilization methods. SPIONs coated with polymers were conjugated with antibodies to target human 
epithelial growth factor receptor 2 (HER-2) to enhance drug delivery to some HER2-overexpressed 
human cancer cells 65. Valero et al. employed the assembly-disassembly process of apoferritin proteins 
driven by pH to form magnetic nanoparticles and further modified the particles via the outer apoferritin 
with carbohydrates to enhance the targeting properties 64. In addition, aptamers are another candidate for 
the modification of SPIONs mixed with plasmonic Au 65, 66. After conjugated, the modified particles 
could be used to collect and detect various cancer cells. Ling et al. coated single chain anti-prostate stem 
cell antigen antibodies (scAb-PSCA) on the SPION surface for the treatment and imaging of prostate 
cancer 67 (Fig. 7). Prostate stem cell antigen (PSCA) is expressed in normal prostate cells and is 
overexpressed in prostate tumor cells 68. The scAb-PSCA served as a linker between SPIONs and 
docetaxel (Dtxl), and it was proven that the scAb-PSCA-Dtxl/SPIONs could be used as a real-time 
monitoring tool for the therapeutic effects and MRI contrast agents for prostate-targeted imaging. The 
cell-based systematic evolution of ligands by exponential enrichment (SELEX) strategies were used to 
scan the affinity of aptamers. The aptamers modified magnetic nanoparticles were used to extract the 
targeted cells while that conjugated with fluorescent particles to detect the cancer cells. 
4.2. Polymeric/silica nanoparticles 
Generally, mesoporous silica nanoparticles (MSNPs) consist of three primary components, including 
a solid support, a payload of cargo, and external machinery. MSNPs have been investigated as effective 
drug delivery systems for therapeutic agents against various diseases 69. It is easy to introduce various 
functional groups onto the nanoparticles by either electrostatic interactions or covalent bonding, 
conferring various mechanized features and high versatility to the mesoporous silica materials. As 
vehicles for the targeted delivery of γ-secretase inhibitors (GSIs), traceable MSNPs were used to block 
Notch signaling. Cell-specific Notch inhibition improved the premature leakage of the drug during its 
delivery. In detail, MSNPs loaded with GSIs were coated with polyethylenimine (PEI) and connected 
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with folic acid to target breast cancer cells. The in vivo data showed that the goal of the targeted delivery 
of MSNPs was realized to some extend (Fig. 8). Furthermore, most of the nanoparticles were eliminated 
via the renal pathway after degradation 70.  
 
Fig. 8 The signal intensity of ex vivo organs (liver, kidney, and spleen) and tumors three days after injection of 
MSNPs. The xenografts were split in half to monitor the distribution of the particles in the tissues (reprinted with 
permission from ref. 70). 
 
In another study, researchers compared the different photodynamic efficacies of silica nanoparticles 
containing phthalocyanine 4 (Pc4) (Pc4SNPs) and free Pc4 solution. Encapsulation of Pc4 into the 
polymeric nanoparticles can avoid fluorescent signal quench in the photodynamic therapy, as well as 
enhance therapeutic efficacy. After encapsulation, the fluorescence spectra and absorption of Pc4SNPs 
were blue-shifted, and the fluorescence intensity of Pc4SNPs was more enhanced than that of free Pc4 at 
the same absorbance. LysoTracker Green DND-26 or MitoTracker Green FM was used to mark the 
lysosomes and mitochondria of A375 and B16F10 cells, as well as colocalize Pc4SNP with these 
organelles. The results confirmed that compared with free Pc4, Pc4SNPs had higher accumulation in the 
mitochondria and lysosomes 71. 
4.3. Polymeric/gold nanoparticles 
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Gold nanoparticles (GNS) are versatile platforms that are highly valued as theranostic systems owing 
to their particular structures and attractive optical properties for photothermal therapy, such as 
near-infrared absorption, surface enhanced Raman scattering, and localized surface plasmon resonance 72, 
73. The surface of GNS can be effortlessly functionalized with ligands and other functional 
chemotherapeutics 74. GNS with core sizes of less than 10 nm provide a large area for ligand modification 
and drug conjugation. They are usually synthesized using hydrogen tetrachloroaurate and have been 
widely investigated as drug carriers, radiosensitizers, photothermal converters, and imaging probes in a 
broad range of applications in cancer diagnosis and therapy 75. Researchers have shown that GNS have 
the potential to heighten the efficacy of conventional treatment modalities and are promising tools in 
diagnostic imaging, minimally invasive thermal ablation therapy, multimodal anti-cancer therapy, and 
intraoperative tumor margin delineation 76.  
Heo et al. designed GNS functionalized with PEG, biotin, paclitaxel, and dye (rhodamine B)-linked 
cyclodextrin derivatives (beta-CD) to undertake therapy and diagnosis simultaneously 77. As a theranostic 
platform, beta-CD interacted with paclitaxel and the two formed an inclusion complex. Thereafter, 
cyclodextrin was connected to the oval GNS with size in the range of 20-40 nm. The in vitro studies 
indicated that GNS had a stronger targeting efficiency toward cancer cells such as HeLa, A549, and 
MG63 than toward NIH/3T3 cells. In addition, GNS possess significant cytotoxicity against HeLa cells. 
The preliminary study supported that GNS are feasible for use in theranostic nanomedicine. In another 
study, researchers utilized gold nanosphere（~33 nm）coated with tumor necrosis factor-alpha (Au-TNF) 
and heated by laser pulses 78 (Fig. 9). To enhance the photothermal efficiency, the researchers 
investigated the influence of nanoparticle structure on therapy and diagnosis. A murine carcinoma model 
was used to compare the therapeutic efficacies of laser with or without Au-TNF conjugates, Au-TNF 
conjugates alone, laser with TNF-free gold nanospheres, and Au-TNF alone. The results confirmed that 
the combination of laser with Au-TNF conjugates resulted in a stronger efficacy toward cancer cells. 
Currently, the photothermal activation of Au-TNF conjugates is in phase II trial in humans. The Au-TNF 
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conjugates can be combined with clinically relevant nanodrugs to acquire synergistic anti-tumor 
theranostic action. 
 
 
Fig. 9 Au-TNF penetration from ear vessels in mice. (a) Window chamber (left) and Photo-acoustic (PA) probe 
(right). (b) Healthy blood vessels. (c) Representative images of Au-TNF within healthy vessels and of (d) Au-TNF 
in the vessels within murine mammary cancer cells tumor before and after administration (i.v.) (reprinted with 
permission from ref. 78). 
4.4. Polymeric/quantum dots 
Quantum dots (QDs) were put forward as a new concept in the 1990s 79. They are nanocrystals made 
of semiconductor materials and have light-emitting properties that can be optimized by tuning their 
composition and size. Most QDs are made up of binary alloys of II-VI or III-V semiconductor materials. 
QDs are crystalline particles and the size of QDs ranges from 1 to 10 nm. QDs are often encapsulated in 
an insulating inorganic shell to increase the quantum yield. The coating materials on the surface of the 
ZnS-capped CdSe QD cores (less than 10 nm) protect it from the microenvironment. It was reported that 
QD-peptide conjugates accumulated in liver tumors 80 (Fig. 10). Ex vitro histological results confirmed 
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that the conjugates were able to target cancer in mice, and the PEG coating significantly lowered the 
reticuloendothelial clearance. However, in vivo detection of the QD signal is challenging. 
 
 
Fig. 10 The colocalization of F3 QDs with vascular tissues within xenograft (reprinted with permission from ref. 
80). 
 
For synchronous traceable drug delivery and cancer imaging, QD (CdSe/ZnS core-shell 
QD490)-aptamer (Apt)-DOX (QD-Apt-DOX) was developed as QD-based theranostics 81. RNA aptamers 
were conjugated onto the diagnostic modality for therapeutic application. Drug sensing was designed on 
the basis of Förster resonance energy transfer (dual donor-quencher) in terms of drug release. When in the 
drug-loading state, the fluorescence of the QDs and the fluorescence of DOX were successively quenched 
by DOX and the aptamer, respectively. During drug release, DOX was liberated from the QD-Apt 
complexes to turn the fluorescence “ON”. The fluorescence of DOX was traced during drug transport. 
This multifunctional QD system heightened the therapeutic specificity against targeted LNCaP cells. The 
drug could be tracked by the fluorescence of Dox during its release and transport. 82 In another study, 
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NIR-emitting CdTe QDs (~ 4.5 nm) were synthesized by attaching cyclicRGD (cRGD) peptides to the 
QDs’ surface. In vivo, the margins of tumor and the tumor itself were visualized and distinguished by the 
resulted QDs. Moreover,  the tumor resection was successfully visualized through NIR imaging 83. 
4.5. Polymeric nanoparticles  
    
Fig. 11 The excitation wavelengths fluctuation of carbon dots in water (excited at from 330 nm to 475 nm) 
(reprinted with permission from ref. 84). 
 
Except for the inorganic contrast agents, some dyes also can be used to monitor the pathway of 
polymeric nanoparticles in vivo. For dyes, the precondition in the clinical application for polymeric 
nanocomposites is penetration to the deep tissue. Therefore, the dyes which can emit far infrared light are 
first choice as an imaging marker in the construction of theranostic nanocomposites. Wolfbeis et al. 
systematically reviewed the difference between fluorescent nanomaterials and nanoparticles versus 
molecular fluorophores, labels and probes in the fluorescent bioimaging. Carbon dots, a cluster of carbon 
atoms have been used to track the kinetics behavior of nanocomposites in vivo. However, the dots with 
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maximum emminsion spectra to 650nm has a lower brightness after the penetration into the deep tissues, 
thus limiting the application in the lab observation and clinical trials (Fig. 11) 84. 
 
5. Application of theranostic nanomaterials in diseases 
The use of nanomaterials in the delivery of drugs or imaging agents 85 has been widely studied. 
However, the integration of drugs and imaging agents into one type of nanoparticle-based theranostic 
platform is a new advance in the past decade 86. Here, we discuss a wide variety of applications of 
theranostic nanomaterials in different diseases. 
5.1. Cancer  
Cancer is one of the most challenging clinical problems and is responsible for approximately 13% of 
all deaths according to the World Health Organization. The complexity of cancer is a major hurdle in the 
treatment of the disease. Although prognosis is improving, the large variety of cancers and metastases 
makes treatment very difficult. Regardless of the treatment method, surgery or chemotherapy, 
visualization of resection or drug transport in the body will reduce relapse and improve the efficacy of 
chemotherapeutics 87. Recently, the development of nanoscale theranostic platforms has facilitated the 
above goals.  
Magnetic direction is feasible for targeted drug delivery with the aid of superparamagnetic and 
magnetic susceptibility. Magnetic nanoparticles can improve the outcomes of clinic therapy and enhance 
brain tumor-targeted drug delivery. EGFR is highly present within glioblastoma (GBM) tumors. And it 
may be a promising target for imaging and therapeutic purposes 88. The wild-type EGFR protein 
constitutes up to 54% of GBM tumors, while co-overexpression of the wild-type EGFR and its receptor 
variant III (EGFRvIII) constitutes up to 31% 89. The specific antibody-modified iron oxide nanoparticles 
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(IONPs) can selectively bind to EGFRvIII on human glioblastoma multiforme (GBM) cells 90. 
Glioblastoma cell survival was significant reduced after administration without significant toxicity to 
human astrocytes. The level of EGFR phosphorylation was reduced in glioblastoma cells after 
EGFRvIIIAb-IONP treatment. Convection-enhanced delivery (CED) of EGFRvIIIAb-IONPs directed by 
MRI promoted the initial distribution of IONPs within or adjacent to the intracranial human xenograft 
tumors and secondary entry into tumor tissues the following day. CED of magnetic nanoparticles 
significantly improved the survival of animals that were implanted with the glioblastoma xenografts. 
IONPs connected with high-affinity antibodies specific to the EGFRvIII-knockout mutant were able to 
selectively enhance MRI contrast and accumulated in the infiltrative glioblastoma cells after CED 90. 
Curcumin and bortezomib can inhibit the growth of cancer cells with a synergistic effect but have no 
anti-osteoclastogenic activity when combined with alendronate (Aln). However, in vivo bioimaging 
showed that Aln-coated nanoparticles entered bone more easily compared with control groups, promoting 
bone resorption and inhibiting tumor growth. GNS can offer a stable microenvironment of biomolecules 
and retain their bioactivity 91. They are currently being studied for drug delivery to pancreatic cancer cells 
92. GNS-based nanomedicine was named CYT-6091 and was used and observed in advanced cancer 
patients 93. The results confirmed that GNS-based nanoparticles were able to significantly reduce the 
systemic toxicity of chemotherapeutics, an effect that may have been due to the inhibition of an off-target 
delivery. Eck et al. prepared GNS linked to a heterobifunctional PEG that were conjugated with 
monoclonal antibodies (mAb F19) to label tumor stroma in thin sections of resected pancreatic 
adenocarcinoma 94 (Fig. 12). Such antibody-conjugated nanoparticles can be used to image pancreatic 
cancer stroma through selective interaction with ﬁbroblast activation protein (FAP). The images feature d 
the tissues in dark field microscopy. This theranostic platform may be subjected to clinical application to 
detect the micrometastasis of pancreatic cancer during surgery. 
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Fig. 12 (A) Representative image of pancreatic cancer tissue (PCT) obtained using immunohistochemistry staining. 
(B) PCT marked by gold nanoparticles (GNS) modified with monoclonal antibody mAb F19 (GNS-F19); (C) 
GNS-F19 localization of healthy tissue by using dark-field microscopy; and (D) PCT marked by GNS-mIgG marker 
(reprinted with permission from ref. 94). 
 
5.2. Cardiovascular diseases  
Cardiovascular diseases (CVDs) encompass a series of conditions, involving vasculature and the 
heart. Generally speaking, when referring to CVDs, atherosclerotic vascular disease and its sequelae, 
including myocardial infarction and stroke, are implied 95. Theranostic strategies for atherosclerotic 
diseases should significantly improve the therapy of cardiovascular conditions. IONPs have been widely 
used for imaging applications 59. This application is very important in atherosclerosis therapy as 
atherosclerosis is difficult to detect before the presence of clinical symptoms 96. 
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Fig. 13 Schematic illustration of preparation of T1-weighted (T1w) theranostic CION (reprinted with permission 
from ref. 98). 
Lanza’s group reported a T1 relaxation effects -weighted (T1w) colloidal iron oxide nanoparticle 
(CION). This nanoparticle was a cross-linked phospholipid nanoemulsion loaded with oleate-coated 
magnetite particles. The nanoemulsion reduced T2 relaxation effects, which significant improved positive 
T1w contrast detection at the nanomolar level 97. Fumagillin was also loaded into the emulsions 
containing CIONs 98 (Fig. 13). Compared with gadolinium, CIONs could effectively reduce T2 relaxation 
times and enhance negative contrast. Surprisingly, when CIONs coated with oleic acid were dispersed 
into almond oil and then entrapped by a mixture of phospholipid surfactants, the effect of T2 was reduced, 
and these nanoparticles became a highly sensitive T1w contrast agent.  
Lopez’s group 99 prepared liposomes that recruited activated macrophages because of the 
metabolically active components from the atheroma tissue. The negatively charged liposomes were 
loaded with dye (rhodamine), GNS, and lipoprotein-associated phospholipase A2 (LAPA-2). LAPA-2 is 
an inflammatory biomarker that is highly expressed on activated macrophages. The group confirmed that 
a high accumulation of liposomes was observed in the shoulder regions of the plaque. They also used 
transmission electron microscopy to image the localization of lipid vesicles within the atheromas by 
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detecting the GNS. These results supported that the liposomes conjugated with lipoprotein-associated 
phospholipase A2 can target the metabolically active regions of plaques. 
5.3. Kidney diseases 
Because the kidneys can quickly eliminate particles that are smaller than 10 nm in diameter, it is a 
candidate organ for the targeted delivery of NPs 100. However, the kidney cannot excrete a particle with a 
diameter of greater than 11 nm because of its anatomical structure 101. Many kidney diseases such as acute 
renal failure (ARF) and chronic kidney disease (CKD) can be treated by NPs.  
For life-threatening ARF, dendrimer NP-based MRI techniques can improve disease detection 102. 
When dendrimers were used to detect ischemia in mice, the data confirmed that the minor increase in the 
tissue range of the kidney was correlated with the time of ischemia and reperfusion 103 (Fig. 14). In 
sepsis-induced ARF models, studies have confirmed that dendrimers loaded with contrast NPs could 
detect kidney injury by MRI before the elevation of serum creatinine 104. This may help eliminate the 
nephrotoxic elements before kidney damage is detectable in serum. Haick et al. used a non-invasive 
means to detect end-stage ''renal disease'' using carbon nanotube in a rat model 105. Work was further 
performed to identify early-stage CKD by using gold NP sensors. Some genetic diseases may cause the 
development of renal cysts. Mutations in polycystic kidney disease 1 (PKD1) or PKD2 lead to autosomal 
dominant PKD (ADPKD) in adults clinically. Europium and terbium phosphors were mixed with 
gadolinium coated on a magnetic core. These theranostic platforms provided strong luminescence and 
feasibility of magnetic manipulations in the detection of human ADPKD and other genetic diseases 106.  
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Fig. 14 The micro-MRI of right kidney center with acute ischemic/reperfusion-induced tubular damage (coronal 
high-resolution images). Time: pre-injection or 0, 6, and 12 min after administration of the diaminobutan 
polypropylenimine diaminobutyl (DAB)-generation 2 dendrimer (0.03 mmol/kg) (reprinted with permission from 
ref. 103). 
 
5.4. Pulmonary diseases 
Although the alveoli are very small, together they offer a large total surface area for efficient gas 
exchange, with a single epithelial cell layer separating air from the capillaries. Meanwhile, the huge 
surface area can also be used to absorb drugs, nanoparticles, and theranostic agents 107.  
Apurva et al. prepared theranostic nanoparticles from DIM-CpPhC6H5 (DIM-P) conjugated with a 
PEGylated CREKA peptide targeting lung cancer and investigated the in vivo anti-tumor activity. 
Imaging techniques were used to analyze targeting efficiency. DIM-CpPhC6H5 encapsulated 
nanoparticles (NCs-D) consisted of lipids and 1,2-dioleoyl-sn-glycero-3-{[N-(5-amino-1-carboxypentyl) 
iminodiacetic acid] succinyl}(nickel salt) (DOGS-NTA-Ni). These NCs-Ds were coated with PEGylated 
CREKA peptides which had a stronger binding ability to plasma proteins and stronger inhibition of tumor 
growth than NCs-D. In vivo imaging confirmed that the migration of PEGylated CREKA peptides in the 
cancer tissue vasculature was 40 times higher than that of NCs-D. The studies demonstrated that the 
Page 27 of 36 Journal of Materials Chemistry B
Jo
ur
na
lo
fM
at
er
ia
ls
C
he
m
is
tr
y
B
A
cc
ep
te
d
M
an
us
cr
ip
t
28 
 
surface of NCs-D conjugated with PEGylated CREKA peptide (PCNCs-D) constitute a promising 
theranostic formulation for lung cancer treatment 108 (Fig. 15). Vij et al. mixed therapeutics and molecular 
probes into a matrix of poly (ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) to prepare 
multifunctional polymeric nanoparticles to treat obstructive lung diseases. Recently, non-invasive 
imaging methods were used to track the distribution and clinic efficacy of nanoparticles in real time for 
chronic obstructive pulmonary disease (COPD) 109.  
 
 
  
Fig. 15 In vivo Image of tumor-bearing mice. (A) A549 (left) and H460 (right) lung tumor cells; (B) PEGylated 
CREKA peptides targeting vessels, and (C) non-targeted vessels (reprinted with permission from ref. 108). 
 
 
5.5. Inflammatory diseases 
Inflammatory diseases are involved in the activation of cellular immune response. Macrophages 
internalize nanoparticles and home to the foci of inflammatory tissues in diseases such as rheumatoid 
arthritis (RA) and multiple sclerosis (MS) 110. Macrophages as target cells uptake particles from blood for 
RA therapy. Researchers have designed RGD-conjugated Au half-shells loaded with methotrexate (MTX) 
to treat RA. MTX is a first line drug that has been widely used for the treatment of RA 111. Heat was 
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locally generated by Au half-shells by near-infrared (NIR) irradiation, resulting in enhanced drug release 
rates and offering thermal therapy and drug treatment to the inflamed joints simultaneously 112 (Fig. 16). 
 
 
Fig. 16 (a) Schematic illustration of RGD-methotrexate-PLGA-Au nanoshell preparation. (b) NIR images of 
inflammatory paws of the collagen-induced arthritis  (CIA) mice confirmed the dynamics of nanoshells at various 
time points (6, 24, 48, and 72 h) after injection of methotrexate-PLGA-Au nanoshells (left) or 
RGD-methotrexate-PLGA-Au nanoshells (right) (reprinted with permission from ref. 112). 
5.6. Neurodegenerative diseases 
Neurodegenerative disorders (NDs) such as Parkinson’s disease and Alzheimer’s disease are 
characterized with progressive loss of neurons’ function and structure 113. The blood-brain barrier is the 
main obstacles to prevent the entry of drugs, nanoparticles, and theranostic agents. Certainly, vascular 
lesions and leakiness of the BBB may provide an opportunity for the penetration of foreign substances 
into cerebral parenchyma.  
Jason et al. confirmed that very small superparamagnetic iron oxide particles (SIOP) can detect 
lesions in the central nervous system in MS animal models, which cannot be achieved by common MRI 
contrast agents 114. Amiri also summarized the advance of magnetic nanoparticles and SIOP as a 
theranostic system for Alzheimer’s disease 115.  
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6. Clinical trials and the commercial market 
Polymeric particulate surfaces provide extensive opportunities for the functionalization of drug 
delivery systems 116, 117. Multimodal conjugated approaches to the treatment and diagnosis of diseases 
could improve the efficacy and specificity of treatment regimes. Currently, some nanoscale drug delivery 
systems such as doxorubicin liposomes (DOXIL Injection) and cytarabine/daunorubicin liposomes 
(CPX-531 formulation) have entered clinical trials as well as commercial markets 118-120. Although 
nanoscale theranostic platforms can deliver active therapeutics and imaging agents, no currently available 
products can be used for the treatment of patients. On the clinical side, Stanley et al. studied the influence 
of 68-Ga-THERANOSTIC, an αvβ3 integrin antagonist, on non-small lung cancer and breast cancer by 
using PET/CT. The data confirmed that compared with Ga, there were many virtues such as safety, 
effectiveness, high tolerance, low irradiation, and convenient labeling, which warranted this platform for 
further clinical trials 121. In another study, PLGA-Au half-shell nanoparticles designed by Park et al. will 
be tested in phase I clinical trials because of their higher therapeutic efficiency caused by the synergistic 
effects of chemotherapeutics and thermotherapy 122. As the first theranostic platform, polymeric 
HPMA-Doxorubicin conjugates labeled with 131I have translated into phase I clinical trial 123. Hopefully, 
theranostic formulations based on real-time detectable signals, positively related to the severity of various 
diseases, can eventually meet the growth requirements in the field of individual therapy in the future 124. 
7. Conclusion and prospect 
Theranostic platforms based on nanomaterials are an emerging area of research integrating targeted 
delivery and local imaging for diagnosis, which further directs the operation of surgery. Because of the 
inheritance of techniques from targeted drug delivery, many strategies have been syncretized, such as 
surface modification, loading process, and tracking drugs in local tissues, which are similar to the loading 
of therapeutics in nanomaterials. However, there are some differences between loading and tracking due 
to the combination and properties of the drug and tracking reagents, such as solubility, polarity, 
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sensitivity to oxide, pH condition, humidity, and light. A reasonable fabrication process and loading 
method should be selected for the protection of drug efficacy and the signal of the imaging reagent. For 
tracking of imaging agent, the big challenge is to improve the metabolism and decrease the deposition of 
inorganic materials in the body. Meanwhile, the sensitivity of signal determines the following application 
of the resulted theranostics in the clinics. The therapeutic effect is based on the targeting efficiency and 
effective drug accumulation; the diagnostic sensitivity is determined by the type and loading efficiency of 
bioimaging agent. In addition, unbeneficial interactions of drug chemicals with imaging molecules, such 
as the complexation, chelation, dye quenching, and drug toxicity, should be avoided. On the other hand, 
the integration of theranostic platforms should place signal tracking, therapeutic efficacy, and synergistic 
effects into first priority. Certainly, efforts may need to be made at the end point to achieve specific aims, 
such as the removal of tumors and localization of thrombi. Researchers should also consider the 
compatibility of drugs and signal substances, preparation cost, equipment design, and feasibility of 
industrialization. Meanwhile, the penetration of signal from deep tissues and the discrimination between 
healthy and abnormal cells would influence the development of theranostic platforms. The chronic 
toxicity of unspecific drug accumulation and the metabolism of metal particles and fluorescent dyes 
would encumber clinical applications after translation 125, 126. Evidently, there is still a long way to go 
before we can achieve a practical theranostic system based on polymeric multifunctional nanomaterials.  
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